PPARA and metabolic syndrome: However, there is a need for new drugs with fewer restrictions on use and an excellent benefit-risk balance, and efforts are being made to develop a drug for dyslipidemias that strengthens the effects of PPARα agonists, as represented by fibrate drugs, but has fewer unfavorable adverse effects.